NYSE:LH

Labcorp Q2 2026 Earnings Report

Labcorp logo
$272.09 +5.75 (+2.16%)
Closing price 06/26/2026 03:59 PM Eastern
Extended Trading
$271.48 -0.61 (-0.22%)
As of 06/26/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Labcorp EPS Results

Actual EPS
N/A
Consensus EPS
$4.79
Beat/Miss
N/A
One Year Ago EPS
N/A

Labcorp Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.71 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Labcorp Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Thursday, July 23, 2026
Conference Call Time
9:00AM ET

Conference Call Resources

Labcorp Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Is Labcorp Holdings Stock Underperforming the Nasdaq?
See More Labcorp Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Labcorp? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Labcorp and other key companies, straight to your email.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE:LH) (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services. Its diagnostics offerings include routine and specialty clinical tests, anatomic pathology, molecular and genomic testing, toxicology and companion diagnostics. On the drug development side, the company provides preclinical and clinical research services, central laboratory support, biomarker development, regulatory and commercialization services to pharmaceutical and biotechnology clients.

The company serves a wide range of customers including physicians, hospitals and health systems, biopharmaceutical companies, employers and public health agencies. Labcorp’s operations extend across the United States and into international markets through laboratory facilities, partnerships and service centers, enabling it to support clinical trials and diagnostic needs on a global scale.

Organized to combine diagnostic testing with drug development capabilities, Labcorp has developed integrated service offerings designed to streamline clinical development and accelerate the translation of laboratory findings into clinical and commercial outcomes. As a publicly traded company, it is positioned to leverage laboratory infrastructure, data analytics and scientific expertise to meet evolving needs in healthcare and life sciences.

View Labcorp Profile